NeurAxis, Inc. (NRXS) AI Stock Analysis

NeurAxis, Inc. is a medical technology firm focused on neuromodulation therapies designed to treat chronic and debilitating conditions in children and adults. Its lead commercial product is IB-Stim, a percutaneous electrical nerve field stimulation system cleared for adolescents aged 11 to 18 with functional abdominal pain linked to irritable bowel syndrome (IBS). The device delivers non-invasive pain relief through targeted electrical nerve stimulation. NeurAxis partners with hospitals and healthcare clinics across the United States to expand access. Founded in 2011 and based in Carmel, Indiana, the firm was formerly known as Innovative Health Solutions, Inc. before rebranding in March 2022.

NeurAxis grew revenue by 32.9% to $3.6M in FY2025, rebounding from $2.7M in FY2024 and $2.5M in FY2023. Five-year revenue compounded at a CAGR of 13.1% from FY2020 to FY2025. Gross margins remained high at 84.2% in FY2025, though lower than 86.5% in FY2024 and 88.9% in FY2022. Operating losses persisted, with an operating margin of -219.4% and net income of -$7.8M in FY2025. For the trailing twelve months ended June 30, 2026, revenue totaled $5.3M, driven by quarterly revenue growth of 115.7% year-over-year, while profit margin stood at -144.4% and EPS was -$0.78.

As of June 30, 2026, NeurAxis held $8.3M in cash and short-term investments against total debt of $279,392, resulting in net cash of $8.0M. Total assets stood at $10.0M and shareholders' equity was $6.7M, supported by a healthy current ratio of 3.04 and a low debt-to-equity ratio of 0.04. Cash flow from operations in FY2025 was -$6.4M, leading to free cash flow of -$6.5M after capital expenditures of $31,150. Share count expanded 125.2% over five years.

At a last close of $7.70, NeurAxis holds a market capitalization of $96.7M and an enterprise value of $83.8M. The stock trades at a price-to-sales multiple of 18.2x and an EV-to-revenue multiple of 15.8x, representing a significant premium to the median of its US-listed Healthcare peers, which carries a price-to-sales ratio of 4.1x. Its price-to-book multiple is 13.6x. NeurAxis shares gained 145.2% over the trailing one-year period, substantially outpacing the S&P 500 (SPY) return of 16.8%, and stand 18.1% above their 200-day average.

NeurAxis is covered by 1 analyst who maintains a Strong Buy rating. The mean price target is $11.00, representing a potential upside of 42.9% above the last close of $7.70. For the fiscal year ending December 31, 2026, the consensus revenue estimate is $8.3M with an EPS projection of -$0.76. For the following fiscal year, 1 analyst projects revenue of $19.8M, representing 138.5% growth, and EPS of -$0.27. The company beat EPS estimates in 3 of the last 4 quarters and is scheduled to report earnings on November 9, 2026.

This page is an AI-written research summary of NeurAxis, Inc. (NRXS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NRXS income statement, NRXS balance sheet, NRXS key metrics, NRXS analyst forecast, NRXS chart. See the NRXS stock overview for the latest quote and news.